This HTML5 document contains 85 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n29http://linked.opendata.cz/resource/drugbank/drug/DB00905/identifier/chebi/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/AHFS/
n9http://linked.opendata.cz/resource/drugbank/company/
n21http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00905/identifier/pharmgkb/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00905/identifier/wikipedia/
n8http://linked.opendata.cz/resource/drugbank/dosage/
n4http://linked.opendata.cz/resource/drugbank/drug/DB00905/identifier/pdb/
n32http://linked.opendata.cz/resource/drugbank/drug/DB00905/identifier/pubchem-compound/
n24http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n31http://linked.opendata.cz/resource/drugbank/drug/DB00905/identifier/pubchem-substance/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00905/identifier/drugbank/
n12http://linked.opendata.cz/resource/drugbank/patent/
n27http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00905/identifier/iuphar/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n25http://linked.opendata.cz/resource/drugbank/drug/DB00905/identifier/guide-to-pharmacology/
n16http://linked.opendata.cz/resource/drugbank/medicinal-product/
n20http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n7http://linked.opendata.cz/ontology/drugbank/
n33http://linked.opendata.cz/resource/drugbank/drug/DB00905/identifier/national-drug-code-directory/
n17http://www.drugs.com/cdi/
n19http://www.rxlist.com/cgi/generic2/
n10http://linked.opendata.cz/resource/drugbank/property/
n6http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n30http://linked.opendata.cz/resource/drugbank/drug/DB00905/identifier/chemspider/
n22http://linked.opendata.cz/resource/atc/
n14http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00905
rdf:type
n7:Drug
n7:description
Bimatoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing the outflow of aqueous fluid from the eyes. It binds to the prostanoid FP receptor.
n7:dosage
n8:271B5CFC-363D-11E5-9242-09173F13E4C5 n8:271B5CFD-363D-11E5-9242-09173F13E4C5 n8:271B5CFE-363D-11E5-9242-09173F13E4C5 n8:271B5CFF-363D-11E5-9242-09173F13E4C5
n7:generalReferences
# Chen MJ, Cheng CY, Chen YC, Chou CK, Hsu WM: Effects of bimatoprost 0.03% on ocular hemodynamics in normal tension glaucoma. J Ocul Pharmacol Ther. 2006 Jun;22(3):188-93. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16808680 # Kruse P, Rieck P, Sherif Z, Liekfeld A: [Cystoid macular edema in a pseudophakic patient after several glaucoma procedures. Is local therapy with bimatoprost the reason?] Klin Monatsbl Augenheilkd. 2006 Jun;223(6):534-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16804825 # Steinhauser SL: Decreased high-density lipoprotein serum levels associated with topical bimatoprost therapy. Optometry. 2006 Apr;77(4):177-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16567279 # Woodward DF, Krauss AH, Chen J, Lai RK, Spada CS, Burk RM, Andrews SW, Shi L, Liang Y, Kedzie KM, Chen R, Gil DW, Kharlamb A, Archeampong A, Ling J, Madhu C, Ni J, Rix P, Usansky J, Usansky H, Weber A, Welty D, Yang W, Tang-Liu DD, Garst ME, Brar B, Wheeler LA, Kaplan LJ: The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol. 2001 May;45 Suppl 4:S337-45. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11434936 # Lim KS, Nau CB, O'Byrne MM, Hodge DO, Toris CB, McLaren JW, Johnson DH: Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008 May;115(5):790-795.e4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18452763 # Brubaker RF: Mechanism of action of bimatoprost (Lumigan). Surv Ophthalmol. 2001 May;45 Suppl 4:S347-51. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11434937 # Christiansen GA, Nau CB, McLaren JW, Johnson DH: Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma. Ophthalmology. 2004 Sep;111(9):1658-62. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15350319 # Easthope SE, Perry CM: Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension. Drugs Aging. 2002;19(3):231-48. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12027782 # Patil AJ, Vajaranant TS, Edward DP: Bimatoprost - a review. Expert Opin Pharmacother. 2009 Nov;10(16):2759-68. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19874254
n7:group
approved investigational
n7:halfLife
Elimination half-life is approximately 45 minutes.
n7:indication
For the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication.
n7:manufacturer
n9:271B5CF5-363D-11E5-9242-09173F13E4C5
owl:sameAs
n24:DB00905 n27:DB00905
dcterms:title
Bimatoprost
adms:identifier
n4:15M n11:PA164748867 n13:Bimatoprost n25:1958 n26:1958 n28:DB00905 n29:51230 n30:4470565 n31:46505334 n32:5311027 n33:0023-3616-03
n7:mechanismOfAction
Bimatoprost is believed to lower intraocular pressure (IOP) in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Bimatoprost reduces the pressure in the eye by mimicking the action of a naturally-occuring prostaglandin. Prostaglandins are a group of chemicals found in many places in the body. In the eye, they increase the drainage of the aqueous humour out of the eyeball. Bimatoprost is a synthetic compound related to one of the natural prostaglandins, and works by increasing the drainage of aqueous humour out of the eyeball. Bimatoprost may also lower the rate of aqueous formation in the eye. Both these effects decrease the pressure within the eye.
n7:packager
n9:271B5CF3-363D-11E5-9242-09173F13E4C5 n9:271B5CF4-363D-11E5-9242-09173F13E4C5
n7:patent
n12:2585691 n12:2144967 n12:6403649 n12:7351404
n7:routeOfElimination
Up to 67% of the administered dose was excreted in the urine while 25% of the dose was recovered in the feces.
n7:synonym
Bimatoprostum (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1e,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide
n7:toxicity
In oral (by gavage) mouse and rat studies, doses up to 100 mg/kg/day did not produce any toxicity. This dose expressed as mg/m<sup>2</sup> is at least 70 times higher than the accidental dose of one bottle of bimatoprost for a 10 kg child.
n7:volumeOfDistribution
* 0.67 L/kg
n14:hasAHFSCode
n15:52-92-00
n7:proteinBinding
Approximately 88% of bimatoprost is bound in human plasma.
n7:synthesisReference
Jiang Xing Chen, "Process for the production of intermediates for making prostaglandin derivatives such as latanaprost, travaprost, and bimatoprost." U.S. Patent US20090287003, issued November 19, 2009.
n20:hasConcept
n21:M0395184
foaf:page
n6:lum1578.shtml n17:bimatoprost-drops.html n19:bimatoprost.htm
n7:IUPAC-Name
n10:271B5D04-363D-11E5-9242-09173F13E4C5
n7:InChI
n10:271B5D0A-363D-11E5-9242-09173F13E4C5
n7:Molecular-Formula
n10:271B5D09-363D-11E5-9242-09173F13E4C5
n7:Molecular-Weight
n10:271B5D06-363D-11E5-9242-09173F13E4C5
n7:Monoisotopic-Weight
n10:271B5D07-363D-11E5-9242-09173F13E4C5
n7:SMILES
n10:271B5D08-363D-11E5-9242-09173F13E4C5
n7:Water-Solubility
n10:271B5D02-363D-11E5-9242-09173F13E4C5 n10:271B5D1A-363D-11E5-9242-09173F13E4C5
n7:logP
n10:271B5D00-363D-11E5-9242-09173F13E4C5 n10:271B5D03-363D-11E5-9242-09173F13E4C5 n10:271B5D1B-363D-11E5-9242-09173F13E4C5
n7:logS
n10:271B5D01-363D-11E5-9242-09173F13E4C5
n14:hasATCCode
n22:S01EE03
n7:H-Bond-Acceptor-Count
n10:271B5D10-363D-11E5-9242-09173F13E4C5
n7:H-Bond-Donor-Count
n10:271B5D11-363D-11E5-9242-09173F13E4C5
n7:InChIKey
n10:271B5D0B-363D-11E5-9242-09173F13E4C5
n7:Polar-Surface-Area--PSA-
n10:271B5D0C-363D-11E5-9242-09173F13E4C5
n7:Polarizability
n10:271B5D0E-363D-11E5-9242-09173F13E4C5
n7:Refractivity
n10:271B5D0D-363D-11E5-9242-09173F13E4C5
n7:Rotatable-Bond-Count
n10:271B5D0F-363D-11E5-9242-09173F13E4C5
n7:absorption
Systemically absorbed when administered to the eye.
n7:affectedOrganism
Humans and other mammals
n7:casRegistryNumber
155206-00-1
n7:category
n7:clearance
* 1.5 L/hr/kg [Healthy subjects receiving IV administration of 3.12 ug/kg]
n7:containedIn
n16:271B5CF6-363D-11E5-9242-09173F13E4C5 n16:271B5CF9-363D-11E5-9242-09173F13E4C5 n16:271B5CFA-363D-11E5-9242-09173F13E4C5 n16:271B5CF7-363D-11E5-9242-09173F13E4C5 n16:271B5CF8-363D-11E5-9242-09173F13E4C5 n16:271B5CFB-363D-11E5-9242-09173F13E4C5
n7:Bioavailability
n10:271B5D16-363D-11E5-9242-09173F13E4C5
n7:Ghose-Filter
n10:271B5D18-363D-11E5-9242-09173F13E4C5
n7:MDDR-Like-Rule
n10:271B5D19-363D-11E5-9242-09173F13E4C5
n7:Number-of-Rings
n10:271B5D15-363D-11E5-9242-09173F13E4C5
n7:Physiological-Charge
n10:271B5D14-363D-11E5-9242-09173F13E4C5
n7:Rule-of-Five
n10:271B5D17-363D-11E5-9242-09173F13E4C5
n7:Traditional-IUPAC-Name
n10:271B5D05-363D-11E5-9242-09173F13E4C5
n7:pKa--strongest-acidic-
n10:271B5D12-363D-11E5-9242-09173F13E4C5
n7:pKa--strongest-basic-
n10:271B5D13-363D-11E5-9242-09173F13E4C5